Ypsomed Holding stock
YPSN.SWSIXYpsomed Holding AG, HealthcareISIN CH0019396990
76Score 76 out of 100, Strong
Price and trend
85 / 100
Price history
+29% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 28% above it.
Since June 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 78).
The price is at its 52-week high. Largest decline in 20 years: 60% (February 2007 to July 2011).
Chart figures for advanced users
- SMA 50$452.99
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$412.05
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)78
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$321.74
- The lowest closing price of the last twelve months.
- Resistance$526.83
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Ypsomed Holding AG belongs to the Medical (Specialties) industry (Switzerland) and, with a market value of $6.93B, is number 5 of 14 companies in its industry on MEQIRI.
- In fiscal 2026 it reported revenue of $880.84M (down 2.4% year on year) and earnings of $267.42M (up 153.6%).
- For fiscal 2027, analysts expect on average revenue of $844.75M (down 4.1%) and adjusted earnings per share of $15.78 (down 19.5%).
Show more
- MEQIRI Score 76 out of 100 (Strong): rank 63 of 714 in Healthcare, median 53.
- The P/E is 26.7 (Healthcare sector median 26.7, own median of recent years 51.7).
- Our model puts fair value at $672.28, with the price 26% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings per share growingUp 104.1% a year since 2021.Growth 77
- High marginNet margin 30.4% over the last 12 months, Medical (Specialties) median 10.4%.Profitability 85
- High return on capitalReturn on invested capital 24% in fiscal 2026, Medical (Specialties) median 4.7%.Profitability 85
Weaknesses
- Margin may fall backOperating margin 33.7%, average of the prior years 12.2%, which ranged from 2.3% to 15.7%. After peaks like this, the margin was more than a quarter lower two years later in 44 of 100 cases, against 24 of 100 for other companies with high margins.
Its standout strengths are momentum and profitability.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What lowers it
- price near its 52-week high
- stable momentum
Valuation
Valuation signal
Significantly undervaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $517.14 and expensive above $960.40 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $817.34 (cash-flow model) and $527.23 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 5.6%. At 6.6% the fair value would be $590.97, at 4.6% it would be $795.56.
Valuation metrics
Half from the cash-flow model, half from earnings times the sector P/E (26.7).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In fiscal 2026, revenue fell 2.4% on the prior year. Revenue has grown solidly since 2007, at about 5% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2026: gross 43%, operating 34%, net 30%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with moderate debt and comfortable interest coverage.
Earnings
- Next earnings
- 26 May 2027in 195 days
- Last reported
- 11 Nov 2026EPS reported $7.76 (expected $6.30)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $15.78+0.2%
- Revenue
- $844.75M−1.2%
- Earnings per share
- $17.72+1.6%
- Revenue
- $931.65M−1.5%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +7.5%Guidance for next year: sales growth of 12% to 15% in Delivery Systems with own devices and EBIT of CHF 210 million to CHF 230 million; free cash flow expected to be positive in 2027 and 2028.
“So EBIT guidance is CHF 210 million to CHF 230 million with the delivery system business with own devices.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 20 May 2026 (fiscal Q4 2026), read by AI.
What happened at Ypsomed Holding
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 76
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Specialties)
The next larger and next smaller companies by market value
- AlconALC.SW $34.65B62
- STERISSTE $24.89B70
- Shanghai United Imaging Healthcare688271.SS $14.35B53
- Sysmex6869.T $7.83B70
- Medacta GroupMOVE.SW $2.64B58
- Eckert & ZieglerEUZ.DE $969.93M74
- QuidelOrthoQDEL $817.18M32
- Mesa LaboratoriesMLAB $782.43M58
ETFs that hold Ypsomed Holding
Held by 10 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF DistX026 | 0.16% | 0.23% | €319.31M |
| Xtrackers MSCI Europe Small Cap UCITS ETF 1CXXSC | 0.12% | 0.30% | €3.43B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.08% | 0.35% | €434.1M |
Show 5 more
| Avantis Global Small Cap Value UCITS ETFAVWS | 0.05% | 0.39% | €1.47B |
| WisdomTree Global Quality Dividend Growth UCITS ETF USD AccWTEM | 0.04% | 0.38% | €1.5B |
| State Street SPDR MSCI Europe Small Cap Value Weighted UCITS ETF EUR AccZPRX | 0.03% | 0.30% | €810.11M |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.02% | 0.45% | €1.53B |
| Vanguard ESG Global All Cap UCITS ETF (USD) AccumulatingV3AA | 0.00% | 0.24% | €1.69B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = CHF 0.8299)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 25 Sep 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.